Moss, 21.08.20
Gentian Diagnostics AS announces its results for the second quarter and first half of 2020. The highlights include:
* Record sales revenues of MNOK 16.6 in 2Q20, up from MNOK 10.2 in 2Q19
* Sales growth in 2Q20 of 64 % is especially based on Cystatin C sales in Asia. Sales in the quarter grew by 44 % YoY on a currency neutral basis
* Successful release of fPELA® turbo, which is marketed by our partner BÜHLMANN
* Gentian awarded up to MNOK 8.0 in funding to support the development of a high-throughput SARS-CoV-2 antibody test
* New scientific publications propose calprotectin as a promising biomarker for the management of COVID-19 patients, which represents a new opportunity for our GCAL® assay
Please find the report and results presentation enclosed. The documents will also be made available on www.gentian.no.
For further information, please contact:
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525